# CeriBell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ceribell

- Industry: Medical Devices & Equipment
- Headquarters: Sunnyvale, US
- Website: www.ceribell.com
- Total disclosed funding: $138M
- Latest round: Series C (Sep 28, 2022)
- Investors on record: 9

## About

CeriBell, Inc. develops innovative EEG technology for the rapid assessment of neurological conditions, focusing on acute care environments such as ICUs and EDs to enhance patient care and diagnosis.Founded in 2014, CeriBell, Inc. is based in Sunnyvale, US, specializing in EEG technology. The company recently completed a Series C funding round led by Ally Bridge Group, raising USD 50.00 mn, bringing total funding to USD 50.00 mn. The founders, Josef Parvizi and Xingjuan Chao, have significant experience in the neurological field. CeriBell has successfully completed 5 deals, with the most recent deal occurring on October 7, 2024.CeriBell specializes in innovative EEG technology designed to enhance the diagnosis and management of neurological conditions, particularly in acute care settings such as intensive care units (ICUs) and emergency departments (EDs). Their flagship product, the Point-of-Care EEG system, provides streamlined and efficient EEG reporting that facilitates rapid assessment of patients for seizure activity. This technology is user-friendly and can be deployed in various healthcare environments, allowing practitioners to obtain critical neurological data quickly and accurately. CeriBell's products are primarily utilized in hospitals across the United States, with adoption in facilities like UCLA, Stanford Health Care, and the University of Kansas Medical Center, among others. The company's offerings address urgent clinical needs, assisting healthcare providers in delivering timely and effective care for patients at risk of seizures and other neurological complications.CeriBell reported revenue of USD 45.23 mn for the year 2023, with an EBITDA of USD -29.19 mn. Revenue is generated through the sale of its EEG technology, focusing on hospitals and healthcare systems that require efficient diagnostic solutions for neurological care. The company utilizes a direct sales model and aims to realize revenue through direct sales of their Point-of-Care EEG systems and potential service agreements for ongoing technical support.CeriBell, Inc. is strategically positioned for growth following its recent IPO on October 7, 2024, raising USD 180 mn by selling 6.7 million shares at USD 17 each, valuing the company at approximately USD 578 mn. The funds from this IPO will support the launch of new products in the EEG technology space and facilitate expansion into new markets, targeting North American healthcare facilities by 2025. The recent funding will also strengthen their market presence as they increase their client base and enhance product development.

## Funding rounds

- Series C, Sep 28, 2022, $50M — Ally Bridge Group
- Series C, Apr 22, 2021, $53M — TPG, Longitude Capital, Redmile Group, RA Capital Management, Red Tree Venture Capital
- Series B, Sep 21, 2018, $36M — TPG, UCB S.A., LivaNova PLC, Optimas Capital Management

## Investors

- TPG (https://capitalatlas.ai/funds/tpg) — Series B, Series C
- UCB S.A. — Series B
- LivaNova PLC — Series B
- Optimas Capital Management (https://capitalatlas.ai/funds/optimas-capital-management) — Series B
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Series C
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C